

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **China Medical & HealthCare Group Limited**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 383)**

### **(1) RE-DESIGNATION OF EXECUTIVE DIRECTOR AS NON-EXECUTIVE DIRECTOR AND (2) CHANGE OF AUTHORISED REPRESENTATIVES**

The Board is pleased to announce that with effect from 1 September 2018 :-

- (1) Dato' Wong Peng Chong will be re-designated from an Executive Director to a Non-Executive Director of the Company and ceased to act as an Authorised Representative of the Company; and
- (2) Ms. Chong Sok Un, an Executive Director of the Company, will be appointed as an Authorised Representative of the Company.

#### **(1) Re-Designation of Executive Director as Non-Executive Director**

The board of directors (the "Board") of China Medical & HealthCare Group Limited (the "Company") is pleased to announce that Dato' Wong Peng Chong ("Dato' Wong") will be re-designated from an Executive Director to a Non-Executive Director of the Company. Accordingly, he has also ceased to act as an authorised representative of the Company (the "Authorised Representative") with effect from 1 September 2018.

Set out below are the biographical details of Dato' Wong :-

Dato' Wong, aged 74, was appointed as executive director of the Company on 15 March 2002. Dato' Wong is a non-executive director of Manfield Chemical Holdings Limited. He is also a director of Asia Development Capital Co., Ltd., a company listed on The Tokyo Stock Exchange, Inc..

Upon his graduation from the University of Malaya in 1967, Dato' Wong joined the Malaysian Foreign Service and served with several Malaysian diplomatic missions overseas in various capacities. He joined the private sector in 1985 and has served in various senior management positions, including executive directorships in public listed companies, in Hong Kong and Malaysia. Dato' Wong was the vice-president of Alibaba Pictures Group Limited from 4 July 2007 to 9 December 2009 and executive director of Landing International Development Limited from 13 October 2009 to 21 January 2010. He was also a director of Mabuhay Holdings Corporation from 23 June 2009 to 27 July 2017 and IRC Properties, Inc. from 6 November 2009 to 27 July 2017 respectively, companies listed on The Philippine Stock Exchange, Inc..

Dato' Wong will enter into a letter of appointment with the Company and the term of his service shall continue for a period of 2 years and shall be renewed automatically for a successive 2-year term or until terminated in accordance with the said letter of appointment. His appointment is also subject to the relevant provisions of retirement and re-election at the annual general meetings of the Company or any other applicable laws whereby he shall vacate his office. Dato' Wong will be entitled to receive HK\$180,000.00 per annum as director's remuneration which is determined by reference to the market salary range for the position and approved by the Board based on his qualifications, experience and level of responsibilities undertaken.

Save as disclosed above, as at the date of this announcement, Dato' Wong confirmed that (i) he does not have any relationship with any directors, senior management, substantial or controlling shareholders of the Company; (ii) he does not have and is not deemed to have any interest in the Shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iii) he has not held any other directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iv) he does not hold other positions with the Company or its subsidiaries; and (v) there is no other matter or information in relation to the appointment of Dato' Wong that needs to be brought to the attention of shareholders of the Company or to be disclosed pursuant to Rule 13.51(2)(h) to 13.51(2)(v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules").

## **(2) Change of Authorised Representatives**

The Board further announces that with effect from 1 September 2018, Dato' Wong will cease to act as an Authorised Representative of the Company under Rule 3.05 of the Listing Rules and the Companies Ordinance (Cap. 622 of the Laws of Hong Kong) (the "Companies Ordinance") and Ms. Chong Sok Un will be appointed as an Authorised Representative of the Company under the Listing Rules and the Companies Ordinance.

By Order of the Board  
**China Medical & HealthCare Group Limited**  
**Dr. Jonathan Weiyan Seah**  
*Chairman*

Hong Kong, 31 August 2018

*As at the date of this announcement, the Board comprises: –*

*Executive Directors*

*Ms. Chong Sok Un (Deputy Chairman), Dato' Wong Peng Chong and Mr. Kong Muk Yin*

*Non-Executive Directors*

*Dr. Jonathan Weiyan Seah (Chairman) and Mr. Liao Feng*

*Independent Non-Executive Directors*

*Mr. Lau Siu Ki, Mr. Zhang Jian and Dr. Xia Xiaoning*